The most ideal treatment for acute cerebral infarction is the recanalization of occlusive vessels as soon as possible. Intravenous thrombolytic therapy is an effective treatment for acute cerebral infarction. Bridging therapy improves the recanalization rate of occlusive vessels, but there are still some patients with residual vascular stenosis. Platelets are known to play an important role in the occurence and development of acute cerebral infarction. One of the key factors for reocclusion of blood vessels after thrombolytic / bridging treatment is the prohibition of antiplatelet aggregation within 24 hours after thrombolytic therapy. Platelet aggregation and activation make a part of the patients with residual artery stenosis reoccluded. Inorder to explore the feasibility and safety of using antiplatelet drugs within 24 hours after intravenous thrombolysis/bridging treatment and improving the prognosis of patients, this paper reviewed the mechanism of platelet activation and the platelet activation status after intravenous thrombolysis/bridging therapy in acute cerebral infarction and the related research of antiplatelet combined with intravenous thrombolysis/bridging therapy.